Evidence map›Paper›PMID 20236514›Full record

ArticleVirology journal2010

Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus.

Chuan-Xi Wang, Yan-Qin Lu, Peng Qi, Long-Hua Chen, Jin-Xiang Han

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Progress and Prospects of Anti-HBV Gene Therapy Development.International journal of molecular sciences · 2015
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Chuan-Xi WangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangdong Province, PR China.
Yan-Qin Lu
Peng Qi
Long-Hua Chen
Jin-Xiang Han
Shandong First Medical University · CNNanfang Hospital · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis delta virus (HDV) ribozyme is an attractive molecular tool that can specifically recognize and catalyze the self-cleavage of the viral RNA phosphodiester backbone. However, a major obstacle in the medical application of the HDV ribozyme is the lack of specificity in the delivery of the ribozyme to defined target cells.

resultsThe objective of this study was to determine whether retroviral vectors can deliver the HDV ribozyme into the target cells and to elucidate whether HDV ribozyme plays a role in hepatitis B virus (HBV) replication. In our study, the transduction of helper-free pseudotyped retrovirus, which showed a broad host range, in human hepatoma cells was performed under 2 conditions, that is, in the presence of polymerized human serum albumin (pHSA) and in the absence of pHSA. The transduction ability in the presence of pHSA was higher than in the absence of pHSA. Moreover, HBsAg and HBeAg levels after transductions with pHSA were significantly lower than those in the absence of pHSA, thus indicating that the recombinant retrovirus had HBV-specific cleavage activity and targeted HepG2215 cells.

conclusionsThese data suggest that this system provides a new approach for targeting hepatocytes and has a great potential in gene therapy for HBV infection.

Indexed as

Antiviral AgentsBiological ProductsCell LineGenetic VectorsHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHepatitis Delta VirusHepatocytesHumansRetroviridaeRNA, CatalyticTransduction, GeneticVirus ReplicationAntiviral AgentsBiological ProductsHepatitis B e AntigensHepatitis B Surface AntigensRNA, Catalytic

Identifiers

PMID20236514
PMCPMC2850903
OpenAlexW2135727854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.